Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019

A 42-year-old man exhibiting hypoxia was diagnosed with coronavirus disease 2019. He had medical histories of type 2 diabetes, hyperlipidemia, hyperuricemia, and gout attack. He received favipiravir for compassionate use for 14 days. Subsequently, he showed increased uric acid levels and developed a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hase, Ryota, Kurata, Rika, Ishida, Keiko, Kurita, Takashi, Muranaka, Emiri, Mito, Haruki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578611/
https://www.ncbi.nlm.nih.gov/pubmed/32727996
http://dx.doi.org/10.2169/internalmedicine.5377-20
_version_ 1783598403855319040
author Hase, Ryota
Kurata, Rika
Ishida, Keiko
Kurita, Takashi
Muranaka, Emiri
Mito, Haruki
author_facet Hase, Ryota
Kurata, Rika
Ishida, Keiko
Kurita, Takashi
Muranaka, Emiri
Mito, Haruki
author_sort Hase, Ryota
collection PubMed
description A 42-year-old man exhibiting hypoxia was diagnosed with coronavirus disease 2019. He had medical histories of type 2 diabetes, hyperlipidemia, hyperuricemia, and gout attack. He received favipiravir for compassionate use for 14 days. Subsequently, he showed increased uric acid levels and developed acute gouty arthritis. Favipiravir may induce not only hyperuricemia but also acute gouty arthritis. It should therefore be used with caution in patients with a history of gout and those with hyperuricemia, especially when used at a higher dose and for a longer duration than is typical.
format Online
Article
Text
id pubmed-7578611
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Japanese Society of Internal Medicine
record_format MEDLINE/PubMed
spelling pubmed-75786112020-10-29 Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019 Hase, Ryota Kurata, Rika Ishida, Keiko Kurita, Takashi Muranaka, Emiri Mito, Haruki Intern Med Case Report A 42-year-old man exhibiting hypoxia was diagnosed with coronavirus disease 2019. He had medical histories of type 2 diabetes, hyperlipidemia, hyperuricemia, and gout attack. He received favipiravir for compassionate use for 14 days. Subsequently, he showed increased uric acid levels and developed acute gouty arthritis. Favipiravir may induce not only hyperuricemia but also acute gouty arthritis. It should therefore be used with caution in patients with a history of gout and those with hyperuricemia, especially when used at a higher dose and for a longer duration than is typical. The Japanese Society of Internal Medicine 2020-07-28 2020-09-15 /pmc/articles/PMC7578611/ /pubmed/32727996 http://dx.doi.org/10.2169/internalmedicine.5377-20 Text en Copyright © 2020 by The Japanese Society of Internal Medicine https://creativecommons.org/licenses/by-nc-nd/4.0/ The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Hase, Ryota
Kurata, Rika
Ishida, Keiko
Kurita, Takashi
Muranaka, Emiri
Mito, Haruki
Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019
title Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019
title_full Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019
title_fullStr Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019
title_full_unstemmed Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019
title_short Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019
title_sort acute gouty arthritis during favipiravir treatment for coronavirus disease 2019
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578611/
https://www.ncbi.nlm.nih.gov/pubmed/32727996
http://dx.doi.org/10.2169/internalmedicine.5377-20
work_keys_str_mv AT haseryota acutegoutyarthritisduringfavipiravirtreatmentforcoronavirusdisease2019
AT kuratarika acutegoutyarthritisduringfavipiravirtreatmentforcoronavirusdisease2019
AT ishidakeiko acutegoutyarthritisduringfavipiravirtreatmentforcoronavirusdisease2019
AT kuritatakashi acutegoutyarthritisduringfavipiravirtreatmentforcoronavirusdisease2019
AT muranakaemiri acutegoutyarthritisduringfavipiravirtreatmentforcoronavirusdisease2019
AT mitoharuki acutegoutyarthritisduringfavipiravirtreatmentforcoronavirusdisease2019

Ejemplares similares